| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,740,000 |
| Market
Cap: |
71.97(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.28 - $21.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients with rare infectious diseases. Co.'s initial product candidate, epetraborole, an antibiotic under development as a once-daily, oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,787,778 |
1,894,632 |
| Total Buy Value |
$0 |
$0 |
$16,053,772 |
$16,898,592 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
9 |
| Total Shares Sold |
0 |
321,491 |
565,631 |
657,255 |
| Total Sell Value |
$0 |
$6,268,666 |
$10,233,675 |
$11,689,612 |
| Total People Sold |
0 |
6 |
6 |
6 |
| Total Sell Transactions |
0 |
12 |
36 |
50 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Readnour Robin Shane |
Director |
– • – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
751,621 |
404,974 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2022-03-29 |
4 |
B |
$15.00 |
$24,999,990 |
I/I |
1,666,666 |
415,612 |
1.5 |
-30% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,999,997 |
299,999 |
|
- |
|
| Aziz Kabeer |
Director |
– • • |
2022-03-29 |
4 |
B |
$15.00 |
$2,499,990 |
I/I |
166,666 |
2,210,735 |
2.25 |
-30% |
|
| Aziz Kabeer |
Director |
– • • |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,430,714 |
386,645 |
|
- |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
4,907 |
4,907 |
|
- |
|
| Adjuvant Global Health Technology Fund De, L.p. |
10% Owner |
– – • |
2022-03-29 |
4 |
B |
$15.00 |
$2,499,990 |
I/I |
166,666 |
2,210,735 |
1.5 |
-30% |
|
| Adjuvant Global Health Technology Fund De, L.p. |
10% Owner |
– – • |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,430,714 |
386,645 |
|
- |
|
| Zakrzewski Joseph S |
Director |
– • – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
98,199 |
98,199 |
|
- |
|
| Marks Gilbert Lynn |
Director |
– • – |
2022-03-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,830 |
|
- |
|
| Eckburg Paul |
Chief Medical OfficerOfficer |
• – – |
2022-03-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
18,289 |
|
- |
|
| Easom Eric |
Chief Executive OfficerOfficer |
• • – |
2022-03-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,294,113 |
|
- |
|
| Zakrzewski Joseph S |
Director |
– • – |
2022-03-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
505,880 |
|
- |
|
88 Records found
|
|
Page 4 of 4 |
|
|
0.05 (2.02%) 
